{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:31:20Z","timestamp":1794947480635,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis Pharma AG"},{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaci.2016.07.038","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T18:37:10Z","timestamp":1473964630000},"page":"1489-1495.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma"],"prefix":"10.1016","volume":"139","author":[{"given":"Carlos","family":"Iribarren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Rahmaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Szefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillis","family":"Carrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Omachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.07.038_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and\u00a0tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"Ayres","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2016.07.038_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1398-9995.2008.01654.x","article-title":"Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma","volume":"63","author":"Humbert","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.07.038_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1081-1206(10)60184-6","article-title":"Baseline characteristics of patients enrolled in EXCELS: a cohort study","volume":"103","author":"Long","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/02770903.2012.690477","article-title":"Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS study","volume":"49","author":"Eisner","year":"2012","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2016.07.038_bib14","series-title":"Early communication about an ongoing safety review of omalizumab (marketed as\u00a0Xolair)","year":"2009"},{"key":"10.1016\/j.jaci.2016.07.038_bib15","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib16","series-title":"CFR-Code of Federal Regulations Title 21","year":"2011"},{"key":"10.1016\/j.jaci.2016.07.038_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2016.07.038_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaci.2016.07.038_bib19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bmj.315.7116.1151","article-title":"Confounding and indication for treatment in evaluation of drug treatment for hypertension","volume":"315","author":"Grobbee","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2016.07.038_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","article-title":"Assessment and control for confounding by indication in observational studies","volume":"47","author":"Psaty","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jaci.2016.07.038_bib21","series-title":"FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events","year":"2014"},{"key":"10.1016\/j.jaci.2016.07.038_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.amjcard.2007.12.024","article-title":"Relation of adult-onset asthma to coronary heart disease and stroke","volume":"101","author":"Onufrak","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaci.2016.07.038_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaci.2008.10.032","article-title":"Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting beta-2-agonists","volume":"123","author":"Appleton","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/aje\/kws181","article-title":"Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts","volume":"176","author":"Iribarren","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaci.2016.07.038_bib25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.rmed.2012.02.017","article-title":"Association of adult-onset asthma with specific cardiovascular conditions","volume":"106","author":"Lee","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/thx.2004.026484","article-title":"Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study","volume":"60","author":"Schanen","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2016.07.038_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00002512-200421060-00005","article-title":"Cardiovascular safety of beta-2-adrenoceptor agonist use in patients\u00a0with obstructive airway disease: a systematic review","volume":"21","author":"Salpeter","year":"2004","journal-title":"Drugs Aging"},{"issue":"suppl\u00a05","key":"10.1016\/j.jaci.2016.07.038_bib28","first-page":"A37","article-title":"Asthma severity and increased risk of cardiovascular and cerebrovascular outcomes in patients with moderate-to-severe persistent asthma","volume":"113","author":"Omachi","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmed.2011.07.021","article-title":"Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study","volume":"106","author":"Cazzola","year":"2012","journal-title":"Respir Med"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaci.2016.07.038_bib30","first-page":"A15991","article-title":"Chronic\u00a0asthma predicts cardiovascular disease events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"130","author":"Tattersall","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2016.07.038_bib31","doi-asserted-by":"crossref","first-page":"e4928","DOI":"10.1136\/bmj.e4928","article-title":"Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study","volume":"345","author":"Fardet","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2016.07.038_bib32","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.2174\/138161210793797870","article-title":"Glucocorticoids and the cardiovascular system: state of the art","volume":"16","author":"Nussinovitch","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaci.2016.07.038_bib33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","article-title":"Use of oral corticosteroids and the risk of acute myocardial infarction","volume":"192","author":"Varas-Lorenzo","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaci.2016.07.038_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.diabres.2010.09.010","article-title":"Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study","volume":"90","author":"Song","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jaci.2016.07.038_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/rheumatology\/kes353","article-title":"Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study","volume":"52","author":"Avi\u00f1a-Zubieta","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2016.07.038_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/art.22548","article-title":"Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica","volume":"57","author":"Maradit Kremers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2016.07.038_bib37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib38","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.038_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/rmed.2001.1256","article-title":"Role of TNF-\u03b1 and its 55 and 75 kDa receptors in bronchial hyperreactivity","volume":"96","author":"Hal\u00e1sz","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000317137","article-title":"Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma","volume":"80","author":"Zietkowski","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.jaci.2016.07.038_bib41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.rmed.2008.10.003","article-title":"High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma","volume":"103","author":"Zietkowski","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2016.07.038_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.038_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0167-5273(91)90216-C","article-title":"Levels of IgE in the serum of patients with coronary arterial disease","volume":"31","author":"Korkmaz","year":"1991","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaci.2016.07.038_bib44","first-page":"122","article-title":"Immunoglobulin E in patients with ischemic heart disease","volume":"15","author":"Sinkiewicz","year":"2008","journal-title":"Cardiol J"},{"key":"10.1016\/j.jaci.2016.07.038_bib45","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/0002-9343(87)90159-8","article-title":"IgE and cardiovascular disease. Results from a population-based study","volume":"82","author":"Criqui","year":"1987","journal-title":"Am J Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916309617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916309617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:03:20Z","timestamp":1758791000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674916309617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0091674916309617"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.07.038","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}